Articel in BioStock: CombiGene raised 75MSEK through rights issue
News 2021 2021 2020 2019 2018 2017 2016 2015 This week, CombiGene announced the outcome of a rights issue, which was was resolved by the board of directors on 8 March 2021 based on the authorisation from the annual general meeting held on 29 June 2020....
read moreCombiGene announces outcome in rights issue
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...
read moreToday, CombiGene Celebrates the World Lipodystrophy Day
News 2021 2021 2020 2019 2018 2017 2016 2015 Currently, there is no cure for lipodystrophy, and just the secondary complications can be treated. Lipodystrophy is a rare and very serious disease. CombiGene continues to develop the pre-clinical work in the...
read moreCG01 project achieves important milestone, initiating preclinical biodistribution and toxicology studies
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene's epilepsy project CG01 is now advancing to the final phase of the preclinical program. Following the release of the material from the first large-scale production of CG01 on March 1,...
read moreCombiGene publishes EU Growth Prospectus relating to the rights issue
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 More information (in swedish) >> The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan,...
read moreThe board of directors of CombiGene resolves on a fully guaranteed rights issue of approximately SEK 75 million
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...
read moreRead about CombiGene’s latest progress and recruitment in Biostock
News 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene advances preclinically and recruits post-docThe interview >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under...
read moreWith the recruitment of Esbjörn Melin, CombiGene further strengthens the company’s scientific position
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene’s epilepsy project CG01 is in late preclinical phase and the company is currently intensifying preparations for the clinical program, where the Phase I study is scheduled to begin in 2022....
read moreThe material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 In the autumn of 2020, CombiGene, together with the Spanish gene therapy manufacturer Viralgen, successfully completed the first large-scale production of the gene therapeutic drug candidate CG01,...
read moreCombiGene is preparing for the clinic, article in BioStock February 23
News 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene is preparing for the clinic, article in BioStock February 23 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better...
read moreCombiGene’s lipodystrophy project receives EUR 882,500 in development funding from the EU Eurostar program
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene’s lipodystrophy project receives EUR 882,500 in development funding from the EU Eurostar program CombiGene is awarded EUR 481,000 in project grants and broadens cooperation in the...
read moreIngeneious #1 2021, News from CombiGene
Ingeneious 2021 2021 2020 2019 2018 2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement...
read moreYear-end statement 2020
Financial reports 2020 2021 2020 2019 2018 2017 2016 2015 2014 2013 Year-end statement 2020 >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No...
read moreInterview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response
News 2021 2021 2020 2019 2018 2017 2016 2015 Yesterday was International Epilepsy Day which aims to put the spotlight on a devastating disease caused by overactive nerve cells in the brain. According to WHO, epilepsy affects about 50 million people...
read moreCombiGene celebrates International Epilepsy Day
News 2021 2021 2020 2019 2018 2017 2016 2015 The International Epilepsy Day is held on the second Monday of February each year. There are 50 million people in the world living with epilepsy, of which 81,000 lives in Sweden. The purpose of International...
read moreResponse from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies
News 2021 2021 2020 2019 2018 2017 2016 2015 In December 2020, CombiGene held separate meetings with the Swedish Medicines Agency and its UK counterpart MHRA (Medicines & Healthcare products Regulatory Agency). The meetings took place after the two...
read moreCombiGene headhunts again
News 2021 2021 2020 2019 2018 2017 2016 2015 With experience from Medical Affairs at MERCK and early drug development at Karo Bio, a solid background in research from a doctoral thesis at Karolinska Institutet and postdoctoral research at Mount Sinai...
read moreWith the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
News 2021 2021 2020 2019 2018 2017 2016 2015 In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies. In parallel, the company will intensify preparations for studies in humans, known as clinical studies, which are scheduled...
read moreBioStock interviews Martin Linhult, CombiGene’s new CMC expert
News 2021 2021 2020 2019 2018 2017 2016 2015 BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01, which is...
read moreAbout CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.
Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden